Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05527626

Chronic Kidney Disease - REAL Life Study in Alsace

Chronic kidney disease (CKD) is a public health problem and affects about 10% of the world's adult population with a constantly increasing incidence. The approach to CKD in France is centered on access to replacement therapy (dialysis, renal transplantation), the cost of which amounts to 4 billion euros (data from the REIN registry).

Real-life data are essential to specify the characteristics of patients with chronic kidney disease and the factors associated with the evolution of CKD and the occurrence of complications in order to improve the management of CKD before the suppletion stage.

Since October 2019, CKD at the severe stage (stage 4) and at the non-dialysis end stage (stage 5) is subject to an annual flat fee (Article L. 162-22-6-2 of the Social Security Code). The reimbursement of these lump sums by the health insurance is subject to the collection and transmission of certain medical data by the establishments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service Néphrologie-Dialyse-Transplantation - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Alexandre Klein, MD

SUB_INVESTIGATOR

Anne-Laure Faller, MD

SUB_INVESTIGATOR

Clotilde Muller, MD

SUB_INVESTIGATOR

Dorothée Bazin, MD

SUB_INVESTIGATOR

François Chantrel, MD

SUB_INVESTIGATOR

Marc Astrié, MD

SUB_INVESTIGATOR

Peggy PERRIN, MD

CONTACT

[email protected]

33 3 69 55 13 26

Peggy PERRIN, MD

PRINCIPAL_INVESTIGATOR

Saïd CHAYER, PhD, HDR

CONTACT

[email protected]

Sophie Caillard, MD

SUB_INVESTIGATOR

Thierry Hannedouche, MD, PhD

SUB_INVESTIGATOR

Thierry Krummel, MD

SUB_INVESTIGATOR

Yves Dimitrov, MD

SUB_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major subject (≥18 years)
  • Subject included in the MRC package (GFR <30 ml/min/1.73 m2)
  • Subject who has not expressed opposition, after information, to the reuse of his or her data for the purpose of this research

Exclusion criteria

  • Subject having expressed his opposition to participate in the study

Treatment and study plan

Primary outcomes

  1. Retroanalysis of the risk factors in patients with severe chronic kidney disease

    Time frame: Files analysed retrospectively from October 01, 2019 to February 31, 2027 will be examined

    Analysis of risk factors in patients with severe chronic kidney disease by retrospectively analyzing health data contained in patient medical records

Study contacts

Contact information is provided by the study sponsor or research team.

Peggy PERRIN, MD

CONTACT

[email protected]

33 3 69 55 13 26

Saïd CHAYER, PhD, HDR

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: CKD-REAL

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Sep 2, 2022
Registry last updated
Nov 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.